FTC Suit Kills Sanofi/Maze Licensing Deal; Will It Doom The Pompe Candidate?

Faced with a lawsuit asserting it had acquired an asset because it was a potential threat, Sanofi bows out of agreement to develop Maze’s GYS1 inhibitor. A test for FTC’s competition theory will be whether MZE001 eventually makes it to the market through other means.